ES2190244T3 - Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales. - Google Patents
Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.Info
- Publication number
- ES2190244T3 ES2190244T3 ES99942350T ES99942350T ES2190244T3 ES 2190244 T3 ES2190244 T3 ES 2190244T3 ES 99942350 T ES99942350 T ES 99942350T ES 99942350 T ES99942350 T ES 99942350T ES 2190244 T3 ES2190244 T3 ES 2190244T3
- Authority
- ES
- Spain
- Prior art keywords
- vertebral
- risk
- partiroid
- hormone
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000010392 Bone Fractures Diseases 0.000 title abstract 2
- 229940088597 hormone Drugs 0.000 title 2
- 239000005556 hormone Substances 0.000 title 2
- 150000001413 amino acids Chemical class 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 abstract 1
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 102000003982 Parathyroid hormone Human genes 0.000 abstract 1
- 108090000445 Parathyroid hormone Proteins 0.000 abstract 1
- 229930003316 Vitamin D Natural products 0.000 abstract 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000000123 anti-resoprtive effect Effects 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 102000058004 human PTH Human genes 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000199 parathyroid hormone Substances 0.000 abstract 1
- 229960001319 parathyroid hormone Drugs 0.000 abstract 1
- 235000019166 vitamin D Nutrition 0.000 abstract 1
- 239000011710 vitamin D Substances 0.000 abstract 1
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 1
- 229940046008 vitamin d Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9715198P | 1998-08-19 | 1998-08-19 | |
| US9974698P | 1998-09-10 | 1998-09-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2190244T3 true ES2190244T3 (es) | 2003-07-16 |
Family
ID=26792729
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99942350T Expired - Lifetime ES2190244T3 (es) | 1998-08-19 | 1999-08-19 | Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales. |
| ES15152726.4T Expired - Lifetime ES2549551T3 (es) | 1998-08-19 | 1999-08-19 | Método para aumentar la tenacidad ósea y la rigidez y reducir las fracturas |
| ES10180447.4T Expired - Lifetime ES2621653T3 (es) | 1998-08-19 | 1999-08-19 | Método para aumentar la tenacidad ósea y la rigidez y reducir las fracturas |
| ES06027055T Expired - Lifetime ES2393200T3 (es) | 1998-08-19 | 1999-08-19 | hPTH(1-34) para uso en la prevención o reducción de la incidencia o gravedad de fractura vertebral y/o no vertebral en un hombre |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15152726.4T Expired - Lifetime ES2549551T3 (es) | 1998-08-19 | 1999-08-19 | Método para aumentar la tenacidad ósea y la rigidez y reducir las fracturas |
| ES10180447.4T Expired - Lifetime ES2621653T3 (es) | 1998-08-19 | 1999-08-19 | Método para aumentar la tenacidad ósea y la rigidez y reducir las fracturas |
| ES06027055T Expired - Lifetime ES2393200T3 (es) | 1998-08-19 | 1999-08-19 | hPTH(1-34) para uso en la prevención o reducción de la incidencia o gravedad de fractura vertebral y/o no vertebral en un hombre |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US6977077B1 (enExample) |
| EP (3) | EP1059933B1 (enExample) |
| JP (5) | JP2002523375A (enExample) |
| KR (1) | KR100454207B1 (enExample) |
| CN (1) | CN1205997C (enExample) |
| AR (1) | AR033639A1 (enExample) |
| AT (1) | ATE231000T1 (enExample) |
| AU (1) | AU746277B2 (enExample) |
| BR (1) | BR9909445A (enExample) |
| CA (1) | CA2325371C (enExample) |
| CO (1) | CO5130020A1 (enExample) |
| CY (2) | CY1113343T1 (enExample) |
| CZ (1) | CZ301017B6 (enExample) |
| DE (2) | DE15152726T1 (enExample) |
| DK (4) | DK1059933T3 (enExample) |
| DZ (1) | DZ2873A1 (enExample) |
| EA (1) | EA003362B1 (enExample) |
| ES (4) | ES2190244T3 (enExample) |
| HR (1) | HRP20000755A2 (enExample) |
| HU (2) | HU1200430D0 (enExample) |
| ID (1) | ID29039A (enExample) |
| IL (2) | IL138829A0 (enExample) |
| MY (1) | MY129227A (enExample) |
| NO (2) | NO323984B1 (enExample) |
| NZ (1) | NZ507056A (enExample) |
| PE (1) | PE20001089A1 (enExample) |
| PL (1) | PL201688B1 (enExample) |
| PT (4) | PT1059933E (enExample) |
| TR (1) | TR200003455T2 (enExample) |
| TW (1) | TW576747B (enExample) |
| UA (1) | UA72205C2 (enExample) |
| WO (1) | WO2000010596A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770623B1 (en) * | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
| AR033639A1 (es) | 1998-08-19 | 2004-01-07 | Lilly Co Eli | Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis |
| US20040033950A1 (en) | 2000-09-26 | 2004-02-19 | Hock Janet M. | Method of increasing bone toughness and stiffness and reducing fractures |
| WO2001022093A1 (en) * | 1999-09-20 | 2001-03-29 | Eli Lilly And Company | Method for monitoring treatment with a parathyroid hormone |
| US7247609B2 (en) | 2001-12-18 | 2007-07-24 | Universitat Zurich | Growth factor modified protein matrices for tissue engineering |
| AU2003207512B2 (en) * | 2002-01-10 | 2008-06-12 | Osteotrophin Llc | Treatment of bone disorders with skeletal anabolic drugs |
| US8088734B2 (en) | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
| NZ545803A (en) * | 2003-09-19 | 2008-03-28 | Wisconsin Alumni Res Found | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and parathyroid hormone |
| US20060052305A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | Method of treating osteoporosis using intranasal parathyroid hormone |
| US20060189533A1 (en) * | 2004-05-10 | 2006-08-24 | Nastech Pharmaceutical Company Inc. | Stable pharmaceutical dosage forms of teriparatide |
| US7244709B2 (en) * | 2004-05-10 | 2007-07-17 | Nastech Pharamecutical Company Inc. | Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
| US20060127320A1 (en) * | 2004-05-10 | 2006-06-15 | Nastech Pharmaceutical Company Inc. | Method of delivering parathyroid hormone to a human |
| MXPA06013168A (es) | 2004-05-13 | 2007-05-15 | Johnson & Johnson | Aparato y metodo para el suministro transdermico de agentes de la hormona paratiroidea. |
| US7648965B2 (en) | 2004-05-14 | 2010-01-19 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
| US20060069021A1 (en) * | 2004-08-13 | 2006-03-30 | Nastech Pharmaceutical Company Inc. | Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs |
| WO2006073711A2 (en) * | 2005-01-06 | 2006-07-13 | Kuros Biosurgery Ag | Use of a matrix comprising a contrast agent in soft tissues |
| US8575101B2 (en) | 2005-01-06 | 2013-11-05 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
| CA2608016A1 (en) * | 2005-05-11 | 2006-11-23 | Unigene Laboratories, Inc. | Improving bone formation and preservation by surgically inducing an increase in osteoblast activity coupled with the effect of administering pthrp or cgrp |
| US20070173447A1 (en) * | 2005-10-25 | 2007-07-26 | Nastech Pharmaceutical Company Inc. | Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent |
| WO2007059470A2 (en) * | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| US20080051332A1 (en) * | 2005-11-18 | 2008-02-28 | Nastech Pharmaceutical Company Inc. | Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone |
| US20080119408A1 (en) * | 2006-07-07 | 2008-05-22 | Nastech Pharmaceutical Company Inc. | Pth formulations for intranasal delivery |
| EP1961765A1 (en) * | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| WO2008125655A1 (en) | 2007-04-13 | 2008-10-23 | Kuros Biosurgery Ag | Polymeric tissue sealant |
| US20110137243A1 (en) * | 2007-09-06 | 2011-06-09 | Abbott Cardiovascular Systems Inc. | Coating On A Balloon Device |
| US9457056B2 (en) * | 2007-12-04 | 2016-10-04 | Ben-Gurion University Of The Negev Research And Development Authority | Peptides comprising alternating hydrophobic and anionic amino acids for treatment of osteoporosis |
| EP2227263A2 (en) | 2007-12-28 | 2010-09-15 | Kuros Biosurgery AG | Pdgf fusion proteins incorporated into fibrin foams |
| ES2662018T3 (es) | 2009-09-09 | 2018-04-05 | Asahi Kasei Pharma Corporation | Agente terapéutico/profiláctico que contiene PTH para la osteoporosis, caracterizado porque la PTH se administra una vez por semana en una dosis unitaria de 200 unidades |
| WO2011071480A1 (en) | 2009-12-07 | 2011-06-16 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| US9295663B2 (en) | 2010-07-14 | 2016-03-29 | Abbott Cardiovascular Systems Inc. | Drug coated balloon with in-situ formed drug containing microspheres |
| WO2012111852A1 (ja) * | 2011-02-17 | 2012-08-23 | 帝人ファーマ株式会社 | 椎体骨折治療剤及びその評価方法 |
| ES2882852T3 (es) | 2011-03-16 | 2021-12-02 | Kuros Biosurgery Ag | Formulación farmacéutica para la utilización en la fusión espinal |
| CN108195965B (zh) | 2011-06-07 | 2021-02-23 | 旭化成制药株式会社 | 含pth肽冷冻干燥制剂的检査方法及包含该含pth肽冷冻干燥制剂的医药品的制造方法 |
| US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| CN108601833B (zh) * | 2016-02-01 | 2022-11-15 | 伊莱利利公司 | 甲状旁腺激素-抗rankl抗体融合化合物 |
| JP2020506926A (ja) * | 2017-02-01 | 2020-03-05 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 副甲状腺ホルモンと変性椎間板疾患の再生 |
| US20200289621A1 (en) * | 2017-09-22 | 2020-09-17 | Asahi Kasei Pharma Corporation | Teriparatide-containing liquid pharmaceutical composition having excellent stability |
| CN111447943A (zh) | 2018-10-29 | 2020-07-24 | 旭化成制药株式会社 | 以按每周2次的频率给予特立帕肽或其盐为特征的骨质疏松症的预防或治疗方法 |
| US12344649B2 (en) | 2019-08-09 | 2025-07-01 | Flagship Pioneering Innovations Vi, Llc | Modulators of parathyroid hormone receptor (PTHR1) |
| GB2590692A (en) * | 2019-12-24 | 2021-07-07 | Corthotec Ltd | Composition for improved bone fracture healing |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086196A (en) | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
| IL78342A (en) * | 1985-04-04 | 1991-06-10 | Gen Hospital Corp | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof |
| DE3935738A1 (de) | 1989-10-27 | 1991-05-08 | Forssmann Wolf Georg | Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff |
| US5208041A (en) | 1991-05-23 | 1993-05-04 | Allelix Biopharmaceuticals Inc. | Essentially pure human parathyroid hormone |
| US5556940A (en) | 1994-06-20 | 1996-09-17 | National Research Council Of Canada | Parathyroid hormone analogues for the treatment of osteoporosis |
| JPH0873376A (ja) * | 1994-09-07 | 1996-03-19 | Asahi Chem Ind Co Ltd | 骨粗鬆症治療薬 |
| US5747456A (en) * | 1994-12-19 | 1998-05-05 | Beth Israel Deaconess Medical Center | Continuous low-dose administration of parathyroid hormone or its agonist |
| EP0800405A4 (en) * | 1994-12-19 | 1998-11-11 | Beth Israel Hospital | CONTINUOUS ADMINISTRATION OF LOW DOSES OF HORMONE PARATHYRO DIENNE OR ITS AGONIST |
| EP1283035A3 (en) * | 1994-12-22 | 2003-03-19 | AstraZeneca AB | Therapeutic preparation for inhalation containing parathyroid hormone |
| JPH08310965A (ja) * | 1995-05-16 | 1996-11-26 | Chugai Pharmaceut Co Ltd | 骨癒合促進剤 |
| BR9812068A (pt) | 1997-09-09 | 2000-09-26 | Hoffmann La Roche | Processo para a cicatrização óssea e restauração de fraturas e utilização de um análogo de polipeptìdeo de peptìdeo (pthrp) relacionado com hormÈnios de paratireóide e seus sais |
| MY120063A (en) | 1997-12-09 | 2005-08-30 | Lilly Co Eli | Stabilized teriparatide solutions |
| US20040033950A1 (en) * | 2000-09-26 | 2004-02-19 | Hock Janet M. | Method of increasing bone toughness and stiffness and reducing fractures |
| AR033639A1 (es) | 1998-08-19 | 2004-01-07 | Lilly Co Eli | Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis |
| US6907597B1 (en) | 2000-10-13 | 2005-06-14 | Ati International Srl | Method and apparatus for constructing an executable program in memory |
| US6967759B2 (en) | 2001-12-31 | 2005-11-22 | Texas Instruments Incorporated | Pulse width modulation sequence generation |
| JP5796714B2 (ja) | 2012-01-13 | 2015-10-21 | 株式会社リコー | 定着装置及び画像形成装置 |
| EP2949301B1 (en) | 2014-05-27 | 2018-04-18 | The Procter and Gamble Company | Absorbent core with curved and straight absorbent material areas |
-
1999
- 1999-08-18 AR ARP990104133A patent/AR033639A1/es unknown
- 1999-08-18 DZ DZ990173A patent/DZ2873A1/xx active
- 1999-08-19 PE PE1999000839A patent/PE20001089A1/es not_active Application Discontinuation
- 1999-08-19 US US09/647,278 patent/US6977077B1/en not_active Expired - Lifetime
- 1999-08-19 ES ES99942350T patent/ES2190244T3/es not_active Expired - Lifetime
- 1999-08-19 UA UA2000095457A patent/UA72205C2/uk unknown
- 1999-08-19 HU HUP1200430 patent/HU1200430D0/hu not_active Application Discontinuation
- 1999-08-19 HR HR20000755A patent/HRP20000755A2/hr not_active Application Discontinuation
- 1999-08-19 DK DK99942350T patent/DK1059933T3/da active
- 1999-08-19 ID IDW20010612A patent/ID29039A/id unknown
- 1999-08-19 IL IL13882999A patent/IL138829A0/xx unknown
- 1999-08-19 BR BR9909445-2A patent/BR9909445A/pt not_active Application Discontinuation
- 1999-08-19 DE DE15152726.4T patent/DE15152726T1/de active Pending
- 1999-08-19 PL PL343595A patent/PL201688B1/pl not_active IP Right Cessation
- 1999-08-19 EP EP99942350A patent/EP1059933B1/en not_active Revoked
- 1999-08-19 AU AU55750/99A patent/AU746277B2/en not_active Expired
- 1999-08-19 PT PT99942350T patent/PT1059933E/pt unknown
- 1999-08-19 TR TR2000/03455T patent/TR200003455T2/xx unknown
- 1999-08-19 HU HU0101594A patent/HU230697B1/hu unknown
- 1999-08-19 ES ES15152726.4T patent/ES2549551T3/es not_active Expired - Lifetime
- 1999-08-19 DK DK06027055.0T patent/DK1769804T3/da active
- 1999-08-19 WO PCT/US1999/018961 patent/WO2000010596A1/en not_active Ceased
- 1999-08-19 EP EP10180447.4A patent/EP2266598B1/en not_active Expired - Lifetime
- 1999-08-19 PT PT06027055T patent/PT1769804E/pt unknown
- 1999-08-19 CN CNB998083534A patent/CN1205997C/zh not_active Expired - Lifetime
- 1999-08-19 PT PT101804474T patent/PT2266598T/pt unknown
- 1999-08-19 CZ CZ20004134A patent/CZ301017B6/cs not_active IP Right Cessation
- 1999-08-19 PT PT15152726T patent/PT2907522T/pt unknown
- 1999-08-19 DK DK10180447.4T patent/DK2266598T3/en active
- 1999-08-19 ES ES10180447.4T patent/ES2621653T3/es not_active Expired - Lifetime
- 1999-08-19 EA EA200001015A patent/EA003362B1/ru not_active IP Right Cessation
- 1999-08-19 ES ES06027055T patent/ES2393200T3/es not_active Expired - Lifetime
- 1999-08-19 EP EP15152726.4A patent/EP2907522B1/en not_active Revoked
- 1999-08-19 AT AT99942350T patent/ATE231000T1/de not_active IP Right Cessation
- 1999-08-19 CO CO99052525A patent/CO5130020A1/es unknown
- 1999-08-19 JP JP2000565916A patent/JP2002523375A/ja active Pending
- 1999-08-19 DK DK15152726.4T patent/DK2907522T3/en active
- 1999-08-19 CA CA002325371A patent/CA2325371C/en not_active Expired - Lifetime
- 1999-08-19 NZ NZ507056A patent/NZ507056A/en not_active IP Right Cessation
- 1999-08-19 DE DE69904918T patent/DE69904918T2/de not_active Expired - Lifetime
- 1999-08-19 MY MYPI99003553A patent/MY129227A/en unknown
- 1999-08-19 KR KR10-2001-7002092A patent/KR100454207B1/ko not_active Expired - Lifetime
- 1999-10-26 TW TW088114185A patent/TW576747B/zh not_active IP Right Cessation
-
2000
- 2000-10-03 IL IL138829A patent/IL138829A/en unknown
- 2000-11-24 NO NO20005947A patent/NO323984B1/no not_active IP Right Cessation
-
2005
- 2005-04-05 US US11/098,894 patent/US7163684B2/en not_active Expired - Lifetime
-
2007
- 2007-06-11 NO NO20072983A patent/NO20072983L/no not_active Application Discontinuation
-
2010
- 2010-10-29 JP JP2010244314A patent/JP2011021035A/ja not_active Withdrawn
-
2012
- 2012-11-14 CY CY20121101096T patent/CY1113343T1/el unknown
-
2014
- 2014-03-25 JP JP2014061763A patent/JP6177718B2/ja not_active Expired - Lifetime
- 2014-10-03 JP JP2014204577A patent/JP2015028065A/ja not_active Withdrawn
-
2017
- 2017-06-26 JP JP2017124301A patent/JP2017190332A/ja not_active Withdrawn
- 2017-10-13 CY CY20171101077T patent/CY1119552T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR033639A1 (es) | Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis | |
| DE3686343D1 (de) | Pharmazeutische zubereitung zur anwendung fuer die anreicherung von knochenmasse. | |
| AR015435A1 (es) | USO DE UN ANÁLOGO POLIPEPTíDICO DEL PÉPTIDO RELACIONADO CON LA HORMONA PARATIROIDEA (PTHRP) Y DE SALES DEL MISMO EN LA PREPARACIoN DE UN MEDICAMENTO. | |
| ES2162615T3 (es) | Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina. | |
| BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
| HUP0003349A2 (hu) | Mellékpajzsmirigy-hormon peptidanalógok, ezeket hatóanyagként tartalmazó gyógyászati készítmények és alkalmazásuk | |
| CL2009000648A1 (es) | Propeptido bmp-11 modificado en el residuo 98 de una secuencia bmp-11 humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; metodo para preparar el propeptido, celula recombinante; uso del propeptido para tratar desordenes musculares, neuromusculares, metabolicos, y degenerativos de los huesos (divisional sol.224-02). | |
| ES2099245T3 (es) | Tratamiento de la osteoporosis usando factor de liberacion de hormona de crecimiento (grf) en combinacion con hormona paratiroidea (pth). | |
| IT1241996B (it) | Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione. | |
| EP1242013A4 (en) | ORAL TRANSMUCOSAL GALENIC FORM USING SOLID SOLUTION | |
| ATE75945T1 (de) | Pharmazeutische zubereitung zur behandlung des diabetes mellitus. | |
| CY1110287T1 (el) | Χρηση της ανθρωπινης παραθυρεοειδους ορμονης | |
| BR9802537A (pt) | Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração | |
| IT1241997B (it) | Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione. | |
| BR0008509A (pt) | Composição farmacêutica oral estabilizada contendo iodeto e iodato e método | |
| ATE273693T1 (de) | Proteinhaltige arzneimittel | |
| ECSP044961A (es) | Acido n-(5-clorosaliciloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides | |
| BR0209748A (pt) | Método para administração oral de hormÈnio paratireóide (pth) | |
| BR9608392A (pt) | Preparação multiparticulada de liberação controlada e forma de dosagem em tablete. | |
| BR0109279A (pt) | Antagonistas de lhrh, sua preparação e aplicação como medicamento | |
| SE8704436D0 (sv) | Anvendning av antisekretoriska substanser for nya indikationer | |
| AR025719A1 (es) | Metodo para tratamiento por monitoreo con una hormona paratiroidea | |
| AR036591A1 (es) | Uso de la hl en hiperestimulacion ovarica controlada | |
| ES2152865A1 (es) | Utilizacion de bisfosfonatos en la preparacion de composiciones farmaceuticas para uso intramuscular. | |
| BR9912260A (pt) | Emplastro contendo um sistema terapêutico transdérmico e dose única para ministração |